Misplaced Pages

Natco Pharma

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Indian pharmaceutical company

Natco Pharma
Company typePublic
Traded asNSE: NATCOPHARM
BSE: 524816
IndustryPharmaceuticals
Founded1981
FounderVC Nannapaneni
HeadquartersHyderabad, Telangana, India
Area servedGlobal
Key peopleVC Nannapaneni (Chairman and MD)
Rajeev Nannapaneni (CEO and Vice Chairman)
RevenueIncrease ₹4,127 crore (US$480 million) (FY24)
Net incomeIncrease ₹1,388 crore (US$160 million) (FY24)
Websitenatcopharma.co.in

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and Agro chemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs. The company specialises in producing complex medicines at affordable prices. NATCO is a science driven company and focuses on limited competition molecules in the US.

History

  • NATCO Pharma was founded in the year 1981 by V C Nannapaneni
  • In 1983 operations commenced at manufacturing facility at Nagarjunasagar, Telangana
  • In 1986 Chemical division commenced at Mekaguda, Telangana
  • In 2008, NATCO Pharma filed its first paragraph IV filing in the US with the USFDA,
  • In 2012, NATCO Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.
  • In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.
  • In 2016, NATCO Pharma launched the first Tamiflu capsule in the US market.
  • In 2019, NATCO Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.
  • In 2022 Crop Health Sciences division launched Chlorantraniliprole (CTPR) based products.
  • NATCO launched the first generic version of Revlimid in the US market
  • For the financial Year 2024, NATCO recorded its highest ever revenue, Earnings Before Interests Tax Depreciation and Amortization and profit after tax.

References

  1. "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
  2. "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
  3. https://www.natcopharma.co.in/wp-content/uploads/2024/05/Q4EarningsPresentation2024.pdf
  4. https://www.natcopharma.co.in/wp-content/uploads/2024/05/Q4EarningsPresentation2024.pdf
  5. "Our Business | Natco Pharma". Retrieved 25 April 2022.
  6. "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
  7. ^ "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
  8. PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
  9. Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
  10. "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
  11. Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
  12. ^ "Niche Play". Business Today. Retrieved 19 April 2020.
  13. "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
  14. "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.
Categories: